We used recombinant SV40 (rSV40)-derived vectors to deliver transgenes to human and simian hematopoietic progenitor cells in culture, and in vivo after transduction ex vivo. rSV40 are highly efficient vectors that are made in very high titers. They infect almost all cells, whether resting or dividing. Two rSV40s were used: SV(HBS), carrying hepatitis B surface antigen as a marker; and SV(Aw) carrying IN#33, a single chain Fv antibody against HIV-1 integrase. CD34
Introduction
Hematopoietic progenitor cells (HPC) are attractive candidates for genetic therapy. Compared with other important target cell populations for gene delivery, the bone marrow is relatively accessible. It can be sampled frequently and the effectiveness of transduction can usually be assessed easily, eg by sampling peripheral blood. HPC give rise to many cellular lineages, one or more branches of which are affected in many inherited and acquired disorders. 1, 2 Gene delivery to hematopoietic cells may even be therapeutic for diseases that affect mainly nonhematopoietic organs. 3 These cells may thus be important transduction targets in treating a wide array of genetic, infectious, neoplastic and other diseases.
Indeed, several initial studies in genetic therapy were conducted using hematopoietic progenitor cells in an attempt to treat adenosine deaminase (ADA) deficiency.
IN#33. Unselected SV(Aw)-transduced CD34
+ cells from HFBM were transplanted into sublethally irradiated SCID mice. Bone marrow harvested 3 months later showed that Ͼ50% of bone marrow cells expressed IN#33. This is comparable with the percentage of human cells in these animals' bone marrow as judged by immunostaining for human CD45. The stability and longevity of transduction in this setting suggests that rSV40 vectors integrate into the cellular genome. This possibility was supported by finding that PCR of genomic DNA using primer pairs with one cellular and one viral primer yielded PCR products only in transduced, but not control, cells. These PCR products hybridized with an SV40 DNA fragment. Thus, rSV40 vectors transduce normal human and primate bone marrow progenitor cells effectively without selection, and maintain transgene expression in vivo following reimplantation. Such high efficiency transduction may be useful in treating diseases of CD34 + cells and their derivatives. Gene Therapy (2000) 7, 886-895.
These pioneering studies showed that genetically modified HPC may persist in the bone marrow, and that their derivatives may persist in the peripheral blood for years. 4, 5 However, experience with ADA deficiency has been sobering in underscoring the limitations of our understanding of these cells and of the difficulties of achieving long-term gene expression in hematopoietic progenitor cells and their derivatives in vivo. 6 Among the obstacles that have hampered gene delivery to HPC have been problems with the vectors that are needed to deliver transgenes to these cells. To date, the principal gene delivery vehicles used for clinical studies of bone marrow cell gene therapy have been derived from Moloney murine leukemia virus (MuLV). 7, 8 Recombinant MuLV viruses (rMuLV) deliver their genes permanently to infected cells, but their effectiveness is limited by several key traits. rMuLV are difficult to produce at high titers, are fragile to manipulation, and generally show low transduction efficiency. More importantly, rMuLV vectors only transduce dividing cells. Thus, HPC or other target cells often must be stimulated ex vivo, and sometimes need to be selected in vitro in order to provide an enriched population of transgene-expressing cells. 2 Transgene expression may also diminish with time, owing largely to inactivation of promoters. [9] [10] [11] [12] Other vector systems that have been developed more recently may circumvent some of these difficulties. Lentivirus vectors, mainly HIV but also including other related viruses, may allow transduction of nondividing bone marrow progenitor cells when packaged in cell lines expressing the G protein of vesicular stomatitis virus (VSV-G). 13, 14 Such vectors can be produced at concentrations 10-to 100-fold higher than are available with oncoretroviral vectors, ie Ϸ10 8 infectious units (IU)/ml. 15 However there are important safety concerns regarding clinical use of lentiviral vectors, and the effects of pseudotyping with VSV-G on clinical utility and vector immunogenicity remain to be elucidated. Another vector system that offers promise in delivering genes to HPC is SV40. Recombinant, large T antigen (Tag)-deleted, SV40 (rSV40) are replication-defective and can be prepared and band-purified to high titers (usually between 10 11 and 10 12 IU/ml). rSV40 can infect almost every mammalian cell type and transduce target cells extremely efficiently. We and others have shown that transducing bone marrow cells with rSV40 carrying marker genes can provide long-term gene delivery to progeny cells (peripheral blood mononuclear cells, PBMC). 16, 17 Further, rSV40 can transduce unstimulated PBMC in culture, also with high efficiency. 18 We describe here the use of rSV40 vehicles for gene delivery to human and nonhuman primate CD34 + bone marrow progenitor cells. rSV40 vectors transduce these cells efficiently without selection and without stimulation, and yield consistent transgene expression that is stable after reimplantation in vivo.
Results

Transduction of human CD34
+ cells by SV(HBS) CD34 + cells were isolated from human fetal bone marrow and treated × 1 with SV40 carrying hepatitis B surface antigen (HBsAg) as a transgene (SV(HBS)). After one cycle of transduction with SV(HBS) × 1 at MOI = 100 IU/cell, CD34
+ cells from human fetal bone marrow (HFBM) were cultured in methylcellulose for 2 weeks. Individual colonies were assayed by PCR for continued carriage of the transgene. These studies were performed Ͼ5 times using CD34 + cells from different human donors. Reproducibly, 50% to 60% of resulting colonies derived from transduced these cells continued to carry the transgene (Figure 1 ). To determine whether carriage of the HBsAg transgene by these cells following transduction was stable for longer periods of time, both uncloned transduced cells and colony outgrowths derived from individual transduced CD34 + cells were cultured without selection for up to 6 weeks after transduction, and then immunostained with antibody to HBsAg. Approximately 50% of the uncloned cells expressed detectable HBsAg by this assay (Figure 2a ). In studies of transduced clonal populations, we found that levels of transgene expression varied substantially from colony to colony. They also fluctuated, albeit to a much lesser extent, within individual colonies. However, colonies that were positive for HBsAg continued to express the transgene for the 6 weeks of this study (Figure 2c ). (Figure 3a) .
We also evaluated persistence of the HBsAg transgene following differentiation of transduced rhesus CD34 + cells into T cells. CD34
+ cells were transduced with SV(HBS) as described above and then cultured on thymic stroma to induce T cell differentiation.
19 CD3 + T cells derived from thymic cultures were purified by cell sorting, and expanded by stimulation with mitogens and irradiated human PBMC in the presence of IL-2. Following over 3 weeks of cell culture after transduction and an over 100-fold expansion of the original transduced cell population, persistence of the transgene was readily detectable by PCR (Figure 3b ).
Delivery of anti-integrase SFv to human CD34
+ cells Having ascertained that rSV40 could deliver transgenes to bone marrow progenitor cells effectively, and that transgene carriage persisted through differentiation into T cells, we asked whether rSV40 could deliver transgenes of potential therapeutic importance, eg to protect T lymphocytes from HIV-1. We have shown that IN#33, a single chain Fv antibody against HIV-1 integrase, protects T cells in culture from infection with HIV-1. IN#33 protects these cells when it is delivered to selected SupT1 human T lymphoma cells by an MuLV vector, 20 or to unselected cells by SV40. 21 As a first step in testing whether SV40 vectors could be adapted to deliver gene therapy to bone marrow progenitor cells to prevent or treat HIV-1 infection, we tested whether we could detect effective transduction of human bone marrow progenitor cells using SV(Aw). SV(Aw) carries IN#33 as a transgene. Expression is driven by CMV-IEP. CD34 + cells from HFBM were treated with SV(Aw). For these studies, somewhat different transduction conditions were used. We have reported Ͼ95% transduction using SV(Aw) to deliver IN#33 to SupT1 T lymphoma cells, using three consecutive daily exposures to the rSV40 virus, first at MOI = 10, then twice at MOI = 3. The human CD34
+ cells were thus treated with SV(Aw) × 3 in this fashion, then cultured for 2 weeks. Cells were either 
Reimplantation of transduced cells in vivo into SCID mice CD34
+ cells from human fetal bone marrow (HFBM) were treated with SV(Aw) × 3, as described. After the third exposure to SV(Aw) they were transplanted into sublethally (375 R) irradiated SCID mice. Such treatment does not ablate the bone marrow, but rather destroys Ϸ50% of the host bone marrow to permit engraftment of the transduced cells in the SCID mouse bone marrow. 22 Three months later, whole bone marrow was harvested from these mice and analyzed for transgene expression. Control mice received HFBM transduced the same way, but with SV(HBS) instead of SV(Aw). When tested for IN#33 expression, Ϸ50% of bone marrow cells harvested from recipients of SV(Aw)-transduced HFBM were positive for transgene expression 3 months after reimplantation of the transduced human fetal bone marrow in vivo ( Figure 6 ). By contrast, bone marrow from mice receiving SV(HBS)-transduced HFBM did not express the IN#33 transgene.
To determine how the percentage of IN#33 + cells correlated with the percentage of human cells in the bone marrow of these mice, the same bone marrow preparations were immunostained with antibody to human CD45. Approximately 50% of nucleated cells in the bone marrow expressed this human cell membrane marker, indicating that the percentage of cells expressing IN#33 was comparable with the percentage of human cells in the reconstituted SCID mouse bone marrow ( Figure 7 ). This percentage is consistent with prior experience in our laboratory 23 and with many published studies.
24,25
Testing for the possibility of integration of rSV40 vectors Data presented here are most consistent with the hypothesis that the rSV40 genome integrates into the cellular genome. To evaluate whether rSV40 transgene delivery persists for such long times because of vector integration, we performed PCR analysis of DNA from SV(HBS)-transduced (× 3) SupT1 human T lymphoid cells. These cells were treated with SV(HBS) × 3 as described above. High molecular weight DNA was prepared by Hirt extraction 26 3, 7, 10 and 14 days following the final treatment. This DNA was amplified by PCR using a primer pair (see Materials and methods), one member of which was from the virus genome while the other was from the human Alu repeat sequences. These primers produced amplification products only in DNA from SV(HBS)-transduced cells; mock-transduced cells were negative (Figure 8a ). To test further whether the amplified DNAs included substantial portions of the SV(HBS) genome near the recognition site for the primer, a 208 bp segment of the SV(HBS) genome adjacent to the site of the viral PCR primer was radiolabeled and used as a probe for the blotted PCR products. Stringent hybridization (50% formamide, 0.1% SDS, 42°C) and final wash (0.1 × SSC, 0.5% SDS, 50°C) conditions were used. The amplified PCR products from SV(HBS)-transduced cells hybridized strongly to the probe. Other lanes were negative (Figure 8b ). Therefore, it is highly likely that SV(HBS) has substantially integrated into the cellular genome within 3 days of transduction. 
Discussion
We have shown that rSV40 vectors can deliver both marker (HBsAg) and potentially therapeutic (IN#33) transgenes to human and nonhuman primate bone marrow progenitor cells effectively, without selection, and with long-term transgene expression in vivo.
Gene Therapy SV40 infects cells, reportedly by binding MHC class I molecules, 27, 28 followed by endocytosis. The endocytic vesicle then apparently transports the virus via the endoplasmic reticulum, 29 through the nuclear membrane and deposits the SV40 particle into the nucleus, where the virus uncoats.
30 rSV40 vectors should thus be able to transduce cells whether or not these cells are cycling at the time of infection. This prediction is consistent with the observation that SV(HBS) transduction of simian CD34
+ cells is comparably efficient whether or not the cells are stimulated by cytokines at the time of transduction. It is further corroborated by our observations that SV40-derived vectors can transduce nondividing cell populations such as neurons 17 and that these vectors can deliver transgenes at high efficiency to the liver (MA Zern and DS Strayer, unpublished; JR Chowdhury and DS Strayer, unpublished).
The need for active cell division for effective transduction with retroviruses has been problematic. This limitation has generally been addressed by transducing ex vivo and simultaneously treating the cells with stimulatory cytokines.
2 Ex vivo culture for transduction does not mimic the hematopoietic microenvironment. Because cytokines that stimulate CD34 + cells to divide also induce them to differentiate, such pretransduction treatment of CD34 + cells often results in transgene delivery to lineagecommitted cells rather than to a self-replenishing pool of multipotent hematopoietic progenitor cells. 8, 31 Clinical studies with such ex vivo transduced CD34
+ cells have shown that circulating transduced cells may persist for long periods of time, but that the numbers of these cells have been small and have generally been well below the therapeutic range. 5, 32 In vivo gene delivery to hematopoietic progenitor cells, if feasible, might resolve some such difficulties, but might introduce others (eg less specificity in the cell population being transduced).
Two other vectors that apparently do not require cell division at the time of transduction have been used for gene delivery to hematopoietic precursor cells: adenoassociated virus (AAV) and, more recently, HIV-1. Gene delivery to bone marrow precursor cells using AAV has been less consistent than that using MuLV. However, when successful, AAV vectors have generally provided more efficient transduction. 33 AAV requires a receptor, heparan sulfate proteoglycan, 34 as well as at least one coreceptor, eg fibroblast growth factor receptor-1 and V␤1a integrin may both serve as coreceptors. 35, 36 The inconsistency of gene delivery by AAV vectors to bone marrow progenitor cells may be due to a high degree Gene Therapy 
HBS). The cells were grown in methylcellulose cultures for 2 weeks, then immunostained using antibody against mouse IgG, with high affinity for murine chain, as described in Materials and methods. In SV(Aw)-transduced clones, almost all cells demonstrated uniform and strong immunofluorescence positivity for the transduced SFv. Two representative clones are shown (A and B). Cells from control (ie SV(HBS)) transduced clones, studied at the same cell density, showed only background fluorescence. A representative SV(HBS)-transduced clone is illustrated in (C).
of variability among the human population in levels of expression of both receptor and coreceptor by CD34 + cells. 37 Gene delivery to hematopoietic progenitor cells by lentiviruses has been described only recently. These viral vectors, whether derived from HIV or other lentiviruses, do not require active cell division for effective transduction.
14,38 They appear to be more efficient than MuLV in delivering transgenes to CD34 + cells as well. 13 However, much more work needs to be done before the full potential of lentiviral gene delivery to bone marrow stem cells is clear.
Figure 6 Transgene expression following implantation of SV(Aw)-transduced human CD34 + cells into SCID mice. Human CD34 + cells derived from human fetal bone marrow were transduced with SV(Aw) as described in Materials and methods. Control cells were transduced similarly with SV(HBS). After 2 weeks in culture, these cells were implanted into sublethally irradiated SCID mice. Three months after implantation, bone marrow cells were harvested and immunostained for expression of the IN#33 transgene, as described in Materials and methods. Approximately 50% of cells in bone marrow specimens from recipients of SV(Aw)-transduced CD34 + cells were positive for Aw (ie IN#33) expression (large arrows). Cells negative for IN#33 expression appeared as faint shadows (small arrows).
In short-term tissue culture studies, rSV40 vectors are highly efficient transducing agents: one exposure provides highly reproducible transduction of 50-60% of colonies derived from transduced progenitor cells. However, when multiple transduction steps are used ex vivo, almost all cells in the culture express the desired transgene for Ͼ2 weeks. By 6 weeks after transduction, immunochemical analysis showed that these cells continued to express the delivered transgenes.
For SV40 gene delivery to be effective in treating such diseases as AIDS, however, transgene carriage must survive differentiation into T lymphocytes and other cells, and transgene expression must persist for long times in vivo. We demonstrated persistence of the SV40-delivered transgene in vitro after progenitor cell maturation to CD3 + Figure 6 cells by culture on thymic stroma. When rSV40-transduced cells were inoculated into sublethally irradiated SCID mice, strong transgene expression was still observed 3 months later. The percentage of transgeneexpressing cells 3 months after re-implantation was similar to the percentage of human cells in the SCID mouse bone marrow. Preliminary data using rSV40-transduced simian CD34
Figure 7 Reconstitution of SCID mouse bone marrow with human cells. The same SCID-hu murine bone marrow specimens tested in
+ cells re-implanted into NOD-SCID mice also support this conclusion (RG Andrews and DS Strayer, unpublished).
The fact that rSV40 persistence and transgene expression continue in large percentages of derivative cells even after months of more or less continuous proliferation in vivo is best explained by postulating that the virus genome integrates into genomes of transduced cells. We tested this possibility by performing PCR on high molecular weight DNA from rSV40-transduced SupT1 cells. rSV40 DNA, if it were present in episomal form, would not be present in preparations of high molecular weight DNA from Hirt extractions, such as we used here. Using a primer combination that should only yield amplicands if rSV40 DNA had integrated near cellular Alu sequences, we found a mixture of different sizes of PCR products that hybridized with viral DNA probes only in transduced cellular DNA. Such analyses provide strong support for random rSV40 integration within 3 days of transduction. Other studies of livers transduced with rSV40 vectors in vivo indicate that substantial integration occurs within 6 h of transduction (JR Chowdhury and DS Strayer, unpublished data, and Ref. 39) .
Because SV40 does not enter cells by phagocytosis, phagolysosomes are not formed. 29 SV40 virions consequently avoid antigen processing at the time of infection. Our rSV40 vectors also lack SV40 large T antigen, the main target recognized by the immune system on virusinfected cells. Tag is also necessary for expression of SV40 capsid proteins. Lacking Tag, and avoiding antigen presGene Therapy
Figure 8 PCR of SV(HBS)-transduced human T cells to test for integration of virus genome into the cellular genome. Human T lymphocytes (SupT1 cells) were treated × 3 with SV(HBS). High molecular weight DNA was then extracted 0, 3, 7, 10 and 14 days thereafter, and subject to PCR analysis. As template 1 g of DNA was used for each condition. PCR primer pairs chosen for this purpose included a primer from the viral genome and a primer from the human Alu repeat sequences (see Materials and methods). After amplification, the reaction products were electrophoresed and visualized using ethidium bromide staining under UV light (upper panel). Negative controls included primer pairs with no added DNA (− con), and DNA from SupT1 cells that were mock-transduced. Following electrophoresis, the gel was blotted to nitrocellulose and probed under very stringent conditions (see Materials and methods) for virus genomic sequences using a 32 P-labeled fragment of the viral genome adjacent to the viral primer used for the PCR. Positivity was visualized by autoradiography (lower panel).
entation at the time of infection, rSV40 vectors are consequently nonantigenic, and can be administered multiply to immunocompetent animals. 40 In theory, then, it should be possible to inoculate rSV40 vectors directly into the bone marrow cavity, and so avoid ex vivo culturing. If levels of the transgene product drop, this process could be easily repeated to boost expression. SV40-based gene delivery vehicles deliver transgenes to the bone marrow cells easily, durably, and with high efficiency. These studies suggest that rSV40 vectors may have a role to play in the genetic therapy of disorders of hematopoietic progenitor cells and their derivatives.
Materials and methods
Cells
Human fetal bone marrow cells were obtained from 18-to 23-week fetuses after the elective termination of pregnancy as described. 41 CD34 + cells were prepared from these cells using MACS CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec, Auburn, CA, USA). 10 7 Cells were resuspended in 90 l of PBS containing 5 mm EDTA and 0.5% bovine serum albumin, 10 l of CD34 MACS Microbeads was added to the suspension. Cells were incubated for 15 min at 12°C, washed once and CD34 + cells isolated using the AutoMACS device.
Rhesus macaque CD34
+ cells were prepared as described. 19 Briefly, heparinized bone marrow was harvested from the posterior iliac crest of anesthetized rhesus monkeys. All animal procedures were performed under protocols approved by the Harvard Medical School Animal Use Committee. Mononuclear cells were separated by centrifugation on Ficoll (Sigma Chemical, St Louis, MO, USA) and were cultured overnight on polystyrene. Remaining erythrocytes were lysed with 0.15 m NH 4 Cl. CD34
+ cells were isolated using magnetic antihuman CD34 + beads that cross-react with rhesus CD34 (Dynal, Lake Success, NY, USA), and separated from these beads using an anti-idiotype antibody (DETACHABEAD; Dynal) according to the manufacturer's protocol. The purity of CD34 + cells obtained using this technique ranged from 93% to 95%. Purified CD34 + cells were further depleted of CD3 + cells by incubation with a CD3-specific antibody (6G12), 42 followed by incubation with sheep anti-mouse magnetic beads (Dynal) and depletion of cells bound to beads using a magnetic separation device (Dynal).
Cell culture SupT1 cells were grown in RPMI-1640, supplemented with 10% fetal bovine serum, penicillin/streptomycin and glutamine (GIBCO-BRL, Gaithersburg, MD, USA).
Human fetal bone marrow cells (HFBM) were cultured in RPMI media with 10% heat-inactivated FBS at 10 7 cells/ml.
Rhesus macaque CD34 + cells were cultured in RPMI (10% FCS, 10 IU/ml penicillin, 10 g/ml streptomycin) at 37°C. Where described, the following cytokines were added to the media: IL-3 (100 ng/ml); IL-6 (20 ng/ml); SCF (100 ng/ml) (all Genzyme, Cambridge, MA, USA).
T cell differentiation of rhesus CD34
+ cells Rhesus CD34
+ cells were induced to differentiate to CD3 + cells by culture on thymic stroma as described. 19 Briefly, thymic tissue was obtained from fetal rhesus macaques (120-160 days gestational age; 165 days is full term) delivered by cesarean section of anesthetized dams. Fetuses were killed with sodium pentabarbital (50-100 mg/kg, intravenously (i.v.)). Thymic tissue was minced into small fragments then digested into single cell suspensions by incubating with phosphate-buffered saline (PBS) with 0.5 mg/ml collagenase (Sigma) and 2 U/ml DNase (Sigma). Thymic stromal cultures were established using either fresh or cryopreserved cells. After 2 days of culture in RPMI-1640, nonadherent cells were removed and the monolayer was maintained in culture media. After 6 days, transduced or untransduced CD34
+ cells were added to the thymic monolayer cultures at 2 × 10 5 cells per well. T cell differentiation was evaluated after 14 days of coculture as previously described.
rSV40
The techniques that are involved in producing and titering recombinant, replication-deficient SV40 derivatives have been described in detail. 17, 43, 44 In general, beginning with the cloned SV40 genome, the early genes (large T antigen, Tag, and small T antigen, tag) are replaced by a polylinker, into which the desired transgene, ± additional promoter, intron, etc, are cloned. Deleting Tag renders the virus replication incompetent and essentially nonimmunogenic. 40 Virus is produced from this cloned genome by excising the virus genome from its carrier plasmid, recircularizing it, and transfecting it into COS-7 cells. These cells supply the necessary Tag protein in trans. Following this initial transfection step, virus is harvested by lysing the transfected cells, and amplified by infecting cultures of COS-7 cells. Subsequent rSV40 preparations are made by amplification using previously produced virus preparations: no further transfection is involved. Helper virus is not used.
Specifically, the two rSV40 used in these studies have been previously reported. 17, 40, 43 SV(HBS) carries the hepatitis B surface antigen gene, expression of which is driven by two tandem SV40 early promoters (SV40-EP). 
21
Transduction with rSV40 Two methods were used to deliver transgenes to cultured bone marrow progenitor cells using rSV40 in these studies. The first approach was to culture the target cells at room temperature with rocking, with rSV40 at multiplicity of infection (virus:cell ratio, MOI) = 100 for 2 h in a minimal culture volume. Cytokines were or were not added to these cultures (see above for specifics), according to the designs of the experiments. After 2 h, medium was added to bring these cultures to their 'usual' volume. Before further manipulation, cultures were allowed to incubate overnight at 37°C.
Additional studies were done using a multiple transduction approach that we have found to be more effective. 21 Virus exposure was performed as described above, with one exception: instead of a single transduction, cells were exposed to virus × 3 on sequential days. The MOI for the first transduction step was 10, while that for the subsequent transductions was 3.
Selection was not used at any time in any of these studies.
Clonogenic cultures
The conditions used to culture HFBM cells, and to clone them, have been described. 23, 45 For these studies, methylcellulose culture was performed in a 1 ml volume, con-893 taining IMDM, 1.2% methylcellulose (Sigma), 30% FBS, 0.2 mm hemin (Sigma), 1% l-glutamine (Gibco, Grand Island, NY, USA) and 5 × 10 −5 m 2-mercaptoethanol. The following combination of cytokines was used in the assay: 20 ng/ml stem cell factor (SCF) (Immunex, Seattle, WA, USA), 50 ng/ml rhIL-3 (Genetics Institute, Cambridge, MA, USA), 10 ng/ml rhIL-6 (Immunex), 6 U/ml rhEpo (Amgen, Thousand Oaks, CA, USA). 2 × 10 3 CD34
+ cells were plated in 35 mm Petri dishes. All the experiments were set up in triplicates and incubated at 37°C in a fully humidified atmosphere with 5% CO 2 (standard conditions). The number of CFU-GM, BFU-E, CFU-GEMM was counted after 14 days of incubation. The conditions used to isolate CD34 + cells from rhesus macaques, and for c.f.u. assays, have been described.
19
SV40-transduced or untransduced populations of CD34 + cells were resuspended in DMEM (2% FCS, 10 IU/ml penicillin, 10 g/ml streptomycin) and then added to complete methylcellulose media with cytokines (IL-3; GM-CSF: erythropoietin; stem cell factor) (Stem Cell Technologies, Vancouver, Canada) and an additional 10 ng/ml IL-3 (Genzyme). 19 Duplicate assays were performed for each condition. After 7-21 days at 37°C with 5% CO 2 , the number of colonies was determined using an inverted light microscope. Positive colonies were scored on the basis of a compact accumulation of 50 or more cells, using standard morphologic criteria.
Re-implantation of transduced cells into SCID mice
Re-implantation of rSV40-transduced HFBM cells into SCID mice followed published protocols. 23 Thus, SCID mice were sublethally irradiated (375 R) and 5 × 10 7 HFBM cells were transplanted i.v. through the tail vein. The animals were killed 3 months later, bone marrow cells were collected and cytospin slides were prepared.
Transgene detection by PCR HBsAg was detected in cloned and uncloned bone marrow progenitor cells and their derivatives by PCR, applying primers specific for the HBsAg gene as described elsewhere. 40 PCR analysis of the HBsAg sequence was performed on colonies derived from CFU cultures. Colonies were harvested into 0.2 ml PCR tubes containing 50 l of phosphate-buffered saline. Colonies were spun down and the supernatant carefully removed using a separate stuffer sterile tip for each colony. Twenty l of lysis buffer (50 mm KCl, 10 mm Tris, 2.5 mm MgCl, 0.5% Tween 20, 0.5% NP-40, Proteinase K 20 g/ml) was added to each colony-containing tube and samples were incubated for 1 h at 55°C, followed by a 15 min incubation at 95°C. One tenth of 2.5 l of lysate was used in each PCR reaction. The PCR reaction was conducted in a 25 l volume using a MJ Research PT-200 DNA Engine (MJ Research, Watertown, MA, USA).
Transgene detection by immunochemistry
HBsAg was also detected in cultured cells by immunochemistry. The techniques used for these studies have been described. Briefly, slides were air-dried, fixed in acetone, and then stained using the ABC technique. 46 To detect HBSAg, anti-HBSAg was used (Vector-Novocastra, Burlingame, CA, USA). Positive staining was visualized after treatment with a secondary antibody by the ABC technique, using horseradish peroxidase and a colored substrate, either aminoethylcarbamizole (which is red) or Gene Therapy diaminobenzidine (which is brown). 46 Slides were counterstained with hematoxylin to visualize nuclei. Controls for these studies included slides treated with normal Ig instead of anti-HBsAg, and mock-infected cells treated with anti-HBSAg.
IN#33 expression was detected by immunofluorescence. Cells were fixed with methanol at room temperature for 10 min and blocked overnight with 1% phosphate-buffered saline/bovine serum albumin (PBS/BSA). The slides were treated overnight with a 1:200 dilution of goat anti-mouse IgG (Nordic Immunology, Tiburg, The Netherlands). This antibody has high activity against mouse chain, and IN#33 is an IgG-SFv. After several washings, cells were incubated with a 1:64 dilution of fluorescein isothiocyanate (FITC)-labeled rabbit anti-goat IgG (Sigma) for 1 h at 37°C. After washing × 5 in PBS, cells were mounted and analyzed by epifluorescence microscopy. Controls for these studies included slides treated with normal Ig instead of antibody to mouse Ig, and SV(HBS)-infected cells treated with anti-mouse Ig.
Extent of repopulation of SCID murine bone marrow by human cells Expression of human CD45 was detected similarly to other cellular proteins mentioned. Monoclonal antibody specific for human CD45 (Becton Dickinson) was used for immunostaining of reconstituted SCID mouse bone marrow slides, and visualized by immunofluorescence as described above.
PCR to amplify combinations of viral and cellular DNA To test for the presence of virus genomic sequences within the cellular genome, we used PCR of high molecular weight DNA to visualize amplicands containing both viral and cellular DNAs. SupT1 cells were transduced with SV(HBS) × 3. DNA was harvested 3, 7, 10 and 14 days after the end of transduction. High molecular weight DNA was prepared by the method of Hirt. 26 The precipitate from this extraction (ie the high molecular weight DNA from SupT1 cells) was analyzed by polymerase chain reaction (PCR). PCR was done using primer pairs comprised of a viral primer and a cellular primer. One PCR primer corresponding to human Alu repeat sequences was used: TCATACACTGCACTCCAGC. It was paired, separately, with either of two viral primers: ACTGTGACTGGTGTGAGCGCTG and TGGACCCAA TGTCTGGGGTC.
Following amplification, PCR products were electrophoresed in agarose gels and visualized using ethidium bromide. These gels were blotted to nitrocellulose filters (S& S, Keene, NH, USA), and visualized following hybridization with a 208 bp radiolabeled probe from the SV40 genome, adjacent to the primer sequences used to produce the amplicands. Conditions for hybridization were 50% formamide, 0.1% SDS, 42°C. Following hybridization, final wash conditions were 0.1 × SSC, 0.5% SDS, 50°C. Visualization was by autoradiography.
